CSX Corporation vs AbbVie

Side-by-side comparison of AI visibility scores, market position, and capabilities

CSX Corporation

LeaderManufacturing

Enterprise

Jacksonville Class I eastern US railroad (NASDAQ: CSX) ~$14.5B 2024 revenue; PSR operating model, new CEO Steve Angel (Sept 2025, ex-Linde), 20,000 route miles competing with Norfolk Southern for eastern freight.

AI VisibilityBeta
Overall Score
A90
Category Rank
#237 of 290
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
90
Perplexity
82
Gemini
93

About

CSX Corporation is a Jacksonville, Florida-based Class I freight railroad — publicly traded on NASDAQ (NASDAQ: CSX) as an S&P 500 Industrials component — operating approximately 20,000 route miles across 26 states in the eastern United States and two Canadian provinces, connecting industrial facilities, ports, agricultural markets, intermodal terminals, and power plants through approximately 22,000 employees. CSX transports merchandise freight (chemicals, automotive, agricultural products, metals, food), intermodal containers and trailers, and coal (utility coal to power plants and export coal to terminals) across the densest rail network in the eastern US, including critical connections to the Port of Baltimore, Port of Savannah, and Port of Norfolk. In fiscal year 2024, CSX reported revenue of approximately $14.5 billion, with the Precision Scheduled Railroading (PSR) operating model maintaining operating ratio efficiency while managing volume volatility from coal headwinds and intermodal competition. A defining leadership development is the September 28, 2025 appointment of Steve Angel as President and CEO, succeeding Joe Hinrichs — Angel brings two decades of operational experience from Linde plc (where he served as CEO from 2018 to 2022 and oversaw the $90B Linde-Praxair merger) and 22 years at General Electric working directly with locomotive and rail operations, bringing a manufacturing and industrial operations discipline to CSX's continued operational improvement agenda.

Full profile

AbbVie

LeaderHealthcare

General

Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.

AI VisibilityBeta
Overall Score
A90
Category Rank
#9 of 1167
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
99
Gemini
83

About

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.

Full profile

AI Visibility Head-to-Head

90
Overall Score
90
#237
Category Rank
#9
73
AI Consensus
60
stable
Trend
stable
90
ChatGPT
99
82
Perplexity
99
93
Gemini
83
91
Claude
96
86
Grok
95

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.